Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
07/01/24, 12:10 PM
Location
bridgewaterIndustry
biotechnology
health care
manufacturing
Type
agreement
Kashiv BioSciences, LLC has announced an exclusive licensing agreement with Amneal Pharmaceuticals, Inc. for ADL018, a proposed biosimilar to omalizumab referencing XOLAIR® for the United States. The biosimilar is currently in a Phase III clinical trial, targeting free IgE to treat chronic conditions such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, food allergies, and chronic spontaneous urticaria.
Company Info
Location
bridgewater, new jersey, united states
Additional Info
Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets. Kashiv BioSciences, LLC in the United States, and its subsidiaries in India (together “Kashiv BioSciences”) operate together with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines.